EN DE
Watch Innospec Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Innospec Inc (IOSP) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Innospec Inc stock $71.71, price $78.21, that is 8.3% below the price, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials US

II Innospec Inc logo Broad data Nov 6, 2026

Innospec Inc

IOSP · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 63/100
Low debt
Generates free cash flow
2.3% dividend yield · Well covered
Ranks above peers (12/15)
Upbeat coverage
Broad data
Profit last quarter +148% vs. a year ago.
Fair value $71.71 · Fairly valued (−8.3%)
Thin margins · 7.5% net margin (TTM)
Moderate moat 48/100 · thin data
Weak Growth (revenue 3y −3.3 %/yr in USD)
⟳ Cyclical
Watch Innospec Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$126.25 $65.12 Fair Value $71.71 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $65.12 – $126.25 · fair‑value band $50.20 – $93.23 · the $78.21 price screens above the $71.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Innospec in your weekly email

Every Wednesday you see whether Innospec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services.

Show moreShow less

It offers specialty chemical products used as additives in diesel, jet, marine, fuel oil, and other fuels used in the operation of commercial trucking, marine and aviation engines, power station generators, heating oil, and other industrial machinery applications.

It also provides technology-based solutions for customers' processes or products in personal care, home care, agrochemical, construction, mining, and other industrial markets.

In addition, the company develops and markets chemical solutions for drilling, completion, production, drag reducing agents, and oil and gas applications.

It serves large multinational companies, manufacturers of personal and home care products and global mining, agriculture and building products, and other industrial companies; national and multinational oil companies, fuel marketers and retailers, fuel terminals, marine lines, coating and plastics producers, and other heavy industrial end-users; and multinational public, independent exploration and production, and oilfield services companies.

The company was formerly known as Octel Corp. and changed its name to Innospec Inc. in January 2006. Innospec Inc. was founded in 1938 and is headquartered in Englewood, Colorado.

Stock analysis

Innospec Inc (IOSP) currently trades at $78.21, while our model-based Fair Value estimate is $71.71, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $91.56 per share, and 11 of the 26 models we run sit above the $78.21 price.

Bear case: the Asset-Based group reads lowest at $20.23, and 15 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: $50.20 (bear) to $93.23 (bull), the price of $78.21 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Innospec Inc reported revenue of $1.8B in FY2025 versus $1.5B in FY2021, a compound +4.6%/yr. Reported net income was $117M in FY2025, compounding +5.8%/yr from FY2021.

Key figures

Market cap $1.9B Small · P/E ratio 14.1 · P/S ratio 1.03 · EPS (TTM) $5.55 · Dividend yield 2.3% · Net margin 7.5% · Return on equity 10.4% · Return on assets (EBIT) 9.7% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −8%, IOSP screens cheaper than that median.

Fair Value models

Bear $50.20 Fair Value $71.71 Bull $93.23
Price $78.21 · Downside -8.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.21 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $43.93 $58.85 $78.65 79
Growth DCF $44.25 $57.34 $73.67 78
Owner Earnings $33.79 $44.32 $58.28 75
All 26 models by family
DCF Models
FCF DCF $43.93 $58.85 $78.65 79
Owner Earnings $33.79 $44.32 $58.28 75
5Y Revenue Exit $56.04 $85.46 $122.89 70
5Y EBITDA Exit $55.51 $84.47 $117.92 73
5Y P/E Exit $55.24 $83.97 $113.77 69
10Y Revenue Exit $49.15 $73.29 $105.37 64
10Y EBITDA Exit $50.32 $72.66 $101.91 66
10Y P/E Exit $50.16 $72.34 $99.02 62
Earnings-Based
Graham-Dodd $32.19 $95.26 $126.03 63
Lynch FV $20.01 $28.59 $37.17 59
PEG = 1.0 $20.01 $28.59 $37.17 55
EPV $53.92 $60.07 $65.22 74
Dividend Discount
Gordon GGM $13.56 $24.69 $34.30 65
DDM Multi-Stage $13.56 $20.74 $26.35 65
Multiples
P/E Multiple $60.36 $80.47 $100.59 63
P/S Multiple $60.36 $80.47 $100.59 58
P/B Multiple $78.50 $104.67 $130.84 55
EV/EBIT $76.36 $98.57 $120.78 66
EV/EBITDA $70.60 $90.89 $111.18 67
EV/Revenue $67.48 $92.23 $116.97 54
Asset-Based
NCAV (Graham) $13.35 $20.23 $25.29 54
Growth DCF
Growth DCF $44.25 $57.34 $73.67 78
Rev-Margin DCF $56.04 $85.32 $118.38 70
Economic Profit
Residual Income $43.67 $46.26 $51.74 74
ROIC Compounder $53.93 $62.65 $72.70 70
Growth Earnings
Growth-Adj P/E $50.20 $71.71 $93.23 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 63/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 41
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 77
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleDavid B. JonesSVP, GC & CCO1,028 shares at $75.64$77,758Mar 3, 2026
  • SaleIan CleminsonEVP & CFO2,380 shares at $76.55$182,197Feb 27, 2026
  • SaleDavid LandlessDirector594 shares at $76.55$45,473Feb 27, 2026
  • SaleClaudia PocciaDirector119 shares at $76.56$9,110Feb 27, 2026
  • SaleLarry PADFIELDDirector2× since Feb 20, 2026: 1,624 shares, avg. $79.91$129,768Feb 27, 2026
  • SaleMilton C BlackmoreDirector2× since Feb 20, 2026: 1,624 shares, avg. $79.91$129,768Feb 27, 2026
  • BuyLeslie J ParretteDirector340 shares at $74.09$25,191Nov 14, 2025

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2020 (pandemic). Over 10 years: +5.8% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+8.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.1%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.5% vs 3.3%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.2% a year for the price and +3.1% for the forecasts.
Forecast 2026 (sales)+7.1%
Forecast 2027 (sales)+5.8%
Projected 2028 (sales)+5.3%
Projected 2029 (sales)+4.9%
Projected 2030 (sales)+4.4%

Watch IOSP, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 21, 2026
AI conclusion: Moderate overall moat with low debt and average returns forms the main strength, while thin evidence prevents confirmation of any durable competitive edge or pricing power.
Main risk: Continued reliance on Middle East activity to drive Oilfield Services recovery risks leaving the new capacity underutilised and mainly offsetting weaker performance in other segments.
Innospec has expanded drag reducing agent capacity in its Oilfield Services segment to capture rising demand. Recovery in that business still depends on Middle East activity picking up as planned while other segments face softer conditions. Will the added production translate into sustained segment growth or mainly cushion slower performance elsewhere?
Join the discussion →

Compare Innospec Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 727 stocks

Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 63 · Top 25%
Fair Value upside −8.3% · Above median
Profitability
Return on equity (12 months) 10.4% · Above median
Return on assets 6.4% · Above median
Net margin (12 months) 7.5% · Above median
Operating margin (12 months) 8.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 7.2% · Below median
Dividend yield (12 months) 2.3% · Above median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 14.1× · Cheaper than median
P/B 1.46× · Cheaper than median
P/S (12 months) 1.03× · Cheaper than median
Price / free cash flow (fiscal year) 22.0× · Pricier than median
EV/EBITDA 8.6× · Cheaper than median
PEG 0.66× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 0
FUTURE (revenue growth)36 · sector 67
PAST (return on equity)42 · sector 26
HEALTH (low debt)98 · sector 95
DIVIDEND (yield)46 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 239.50 TWD 383.20 TWD +60% vs IOSP
Wanhua Chemical Group 600309 ¥72.65 ¥68.03 −6% vs IOSP
Linde plc LIN $515.25 $446.62 −13% vs IOSP
PPG Industries, Inc PPG $122.38 $77.68 −37% vs IOSP
DSM-Firmenich AG DSFIR CHF 100.50 CHF 57.70 −43% vs IOSP
The Sherwin-Williams Company SHW $344.10 $146.37 −57% vs IOSP
Givaudan SA GIVN CHF 4,054 CHF 1,554 −62% vs IOSP
EMS-CHEMIE HOLDING AG EMSN CHF 848.50 CHF 284.63 −66% vs IOSP
Ecolab Inc ECL $300.68 $96.56 −68% vs IOSP
Air Products and Chemicals, Inc APD $304.84 $82.92 −73% vs IOSP

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Innospec Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Innospec Inc Fair Value". https://www.fairvalue-calculator.com/stock/IOSP

Frequently asked questions

Is Innospec Inc (IOSP) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $71.71 versus a price of $78.21, about 8% lower (fairly valued).
What is the fair value of IOSP?
Our model-based fair value for Innospec Inc is $71.71 (as of Nov 6, 2026), built from audited fundamentals. The current price: $78.21.
What is the quality score of IOSP?
Innospec Inc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innospec Inc (IOSP)?
Our model-based price target is the fair value of $71.71 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario $50.20, optimistic scenario $93.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Innospec Inc stock forecast for 2026?
Our models put fair value at $71.71, about 8% lower versus a price of $78.21 (fairly valued). Cautious scenario $50.20, optimistic scenario $93.23. The calculation is refreshed regularly with new filings.
What is the revenue of Innospec Inc (IOSP)?
Innospec Inc reported trailing-twelve-month revenue of about $1.9B (latest available figure, as of Nov 6, 2026).
Does Innospec Inc pay a dividend?
Innospec Inc currently shows a dividend yield of 2.29% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Innospec Inc (IOSP) and when is the ex-dividend date?
Innospec Inc pays a dividend of $1.79 per share a year, a dividend yield of 2.3%. The last ex-dividend date was May 19, 2026. A dividend has been paid every year since 2012. The payout ratio is 28.7% of earnings (on adjusted earnings, reported 32.3%). Free cash flow covers the dividend 2.00 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Innospec Inc (IOSP)?
For today's price to be fair in a discounted-cash-flow model, Innospec Inc would have to grow free cash flow by +11.8 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of IOSP use?
Our models discount Innospec Inc at 10.8 %: a base by market capitalisation (small), damped by beta 0.85, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Innospec Inc that is +11.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Innospec Inc (IOSP) delivered so far?
Over the past 5 years revenue at Innospec Inc grew +8.3 % a year. The price currently implies free-cash-flow growth of +11.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Innospec Inc (IOSP) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Innospec Inc (+11.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Innospec Inc (IOSP)?
The free-cash-flow yield on the price is 4.55 %: that much free cash flow Innospec Inc produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Innospec Inc (IOSP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innospec Inc it is $71.71 per share (as of Nov 6, 2026), against a price of $78.21. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Innospec Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, IOSP trades above its calculated fair value: price $78.21, fair value $71.71, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IOSP?
No. The price is what the market pays today ($78.21); the fair value is what the company's own numbers justify ($71.71). For Innospec Inc the two are $6.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innospec Inc worth?
The market values Innospec Inc at about $1.9B (market capitalisation, as of Nov 6, 2026). Per share that is $78.21; our models calculate a fair value of $71.71 per share.
What do the bullish and bearish scenarios say about IOSP?
Our models span a range for Innospec Inc: cautious scenario $50.20, base $71.71, optimistic $93.23 per share (as of Nov 6, 2026, price $78.21). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IOSP?
Innospec Inc trades at a price-to-earnings ratio of 14.1 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $71.71 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 14.8 (reported for FY2025: 16.7). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 6 of the years ex one-offs: 23.1. Other multiples: PEG 0.7, P/B 1.5, P/S 1.0, EV/EBITDA 8.6.
What is the PEG ratio of IOSP?
The PEG ratio of Innospec Inc is 0.66 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Innospec Inc (IOSP)?
Balance-sheet figures for Innospec Inc (as of Nov 6, 2026): return on equity 10.4%, debt of 0.04 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is IOSP from its 52-week high?
Innospec Inc trades at $78.21, about 23% below its 52-week high of $101.41 and 20% above the low of $65.12 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $71.71 is for.
Which stocks are comparable to Innospec Inc?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innospec Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $78.21, calculated fair value $71.71 (−8%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IOSP calculated?
We run Innospec Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $71.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Innospec Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innospec Inc (IOSP)?
The closing price on Nov 6, 2026 was $78.21. Our model-based fair value is $71.71, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innospec Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($50.20 to $93.23) leaves room in how you read the outcome.
Where does the earnings growth of Innospec Inc (IOSP) come from?
Earnings per share at Innospec Inc grew +0.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.5 %, EBIT margin −4.2 %, tax rate +0.6 %, residual (interest, one-offs) −3.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Innospec Inc

How large is the market capitalisation of Innospec Inc (IOSP)?
The market capitalisation of Innospec Inc is $1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innospec Inc (IOSP)?
The price-to-sales ratio of Innospec Inc is 1.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innospec Inc (IOSP)?
Earnings per share at Innospec Inc are $5.55 (price ÷ EPS = P/E 14.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Innospec Inc (IOSP)?
The dividend yield of Innospec Inc is 2.3% (payout 28.7%, on adjusted earnings, reported 32.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Innospec Inc (IOSP)?
The net margin of Innospec Inc is 7.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Innospec Inc (IOSP)?
The return on equity (ROE) of Innospec Inc is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innospec Inc (IOSP)?
On an EBIT basis the return on assets of Innospec Inc is 9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innospec Inc (IOSP)?
The operating margin of Innospec Inc is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innospec Inc (IOSP)?
Revenue at Innospec Inc is growing +7.2% versus a year earlier (3y avg −3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Innospec Inc (IOSP)?
Earnings per share at Innospec Inc are growing +148% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Innospec Inc (IOSP) hold?
Innospec Inc holds more cash than debt, $240M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Innospec Inc in the live analysis

One click puts Innospec Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.